Table S2.
Bucher indirect meta-analysis of American College of Rheumatology (ACR) criteria scores of 20, 50, and 70 outcomes: combination therapy
| Treatment | Control | Fixed effect | Random effects | ||
|---|---|---|---|---|---|
|
|
|
||||
| OR v control (95% CI) | P-value | OR v control (95% CI) | P-value | ||
| ACR 20 | |||||
| ETN 2 × 25 mg/week + DMARD | ABA 10 mg/kg/4 weeks + DMARD | 2.736 (1.495, 5.008) | 0.001 | 2.7 (1.47, 4.959) | 0.001 |
| ETN 2 × 25 mg/week + DMARD | ADA 40 mg/2 weeks + DMARD | 2.388 (1.286, 4.436) | 0.006 | 2.429 (1, 5.899) | 0.050 |
| ETN 2 × 25 mg/week + DMARD | CZP 200 mg/2 weeks + DMARD | 0.775 (0.398, 1.508) | 0.452 | 0.766 (0.383, 1.53) | 0.449 |
| ETN 2 × 25 mg/week + DMARD | GOL 50 mg/4 weeks + DMARD | 2.389 (1.143, 4.99) | 0.021 | 2.354 (1.123, 4.935) | 0.023 |
| ETN 2 × 25 mg/week + DMARD | INF 3 mg/kg/8 weeks + DMARD | 2.407 (1.328, 4.362) | 0.004 | 2.409 (1.282, 4.528) | 0.006 |
| ETN 2 × 25 mg/week + DMARD | RTX 2 × 1000 mg + DMARD | 2.307 (1.157, 4.602) | 0.018 | 2.277 (1.138, 4.556) | 0.020 |
| ETN 2 × 25 mg/week + DMARD | TOC 8 mg/kg/4 weeks + DMARD | 1.83 (1.011, 3.313) | 0.046 | 1.809 (0.996, 3.287) | 0.052 |
| ACR 50 | |||||
| ETN 2 × 25 mg/week + DMARD | ABA 10 mg/kg/4 weeks + DMARD | 2.98 (1.386, 6.411) | 0.005 | 2.87 (1.333, 6.18) | 0.007 |
| ETN 2 × 25 mg/week + DMARD | ADA 40 mg/2 weeks + DMARD | 2.7 (1.241, 5.876) | 0.012 | 2.424 (0.704, 8.355) | 0.161 |
| ETN 2 × 25 mg/week + DMARD | CZP 200 mg/2 weeks + DMARD | 1.095 (0.463, 2.594) | 0.836 | 1.037 (0.395, 2.723) | 0.942 |
| ETN 2 × 25 mg/week + DMARD | GOL 50 mg/4 weeks + DMARD | 2.176 (0.862, 5.498) | 0.100 | 2.056 (0.729, 5.8) | 0.173 |
| ETN 2 × 25 mg/week + DMARD | INF 3 mg/kg/8 weeks + DMARD | 2.774 (1.298, 5.929) | 0.008 | 2.723 (1.202, 6.169) | 0.016 |
| ETN 2 × 25 mg/week + DMARD | RTX 2 × 1000 mg + DMARD | 2.58 (1.059, 6.282) | 0.037 | 2.481 (1.018, 6.05) | 0.046 |
| ETN 2 × 25 mg/week + DMARD | TOC 8 mg/kg/4 weeks + DMARD | 1.674 (0.78, 3.594) | 0.186 | 1.689 (0.76, 3.757) | 0.199 |
| ACR 70 | |||||
| ETN 2 × 25 mg/week + DMARD | ABA 10 mg/kg/4 weeks + DMARD | 4.144 (0.914, 18.784) | 0.065 | 4.149 (0.867, 19.84) | 0.075 |
| ETN 2 × 25 mg/week + DMARD | ADA 40 mg/2 weeks + DMARD | 4.257 (0.935, 19.385) | 0.061 | 4.138 (0.682, 25.104) | 0.123 |
| ETN 2 × 25 mg/week + DMARD | CZP 200 mg/2 weeks + DMARD | 1.416 (0.274, 7.31) | 0.678 | 1.536 (0.298, 7.909) | 0.608 |
| ETN 2 × 25 mg/week + DMARD | GOL 50 mg/4 weeks + DMARD | 3.212 (0.591, 17.462) | 0.177 | 3.279 (0.606, 17.743) | 0.168 |
| ETN 2 × 25 mg/week + DMARD | INF 3 mg/kg/8 weeks + DMARD | 4.899 (1.098, 21.858) | 0.037 | 5.213 (1.171, 23.213) | 0.030 |
| ETN 2 × 25 mg/week + DMARD | RTX 2 × 1000 mg + DMARD | 6.687 (1.317, 33.953) | 0.022 | 6.206 (1.035, 37.223) | 0.046 |
| ETN 2 × 25 mg/week + DMARD | TOC 8 mg/kg/4 weeks + DMARD | 1.916 (0.42, 8.739) | 0.401 | 2.151 (0.418, 11.083) | 0.360 |
Note:P < 0.05 is statistically significant.
Abbreviations: ABA, abatacept; ADA, adalimumab; ANA, anakinra; CI, confidence interval; CZP, certolizumab pegol; DMARD, disease-modifying antirheumatic drug (MTX or SUL); ETN, etanercept; exp, experienced; GOL, golimumab; INF, infliximab; MTX, methotrexate; OR, odds ratio; RTX, rituximab; SUL, sulfasalazine; TOC, tocilizumab.